Britain's GlaxoSmithKline (NYSE: GSK )
isn't built to run like a gazelle, but it has a pretty diverse
business that addresses multiple large therapeutic areas like
respiratory, vaccines, HIV, and consumer health. The company has taken
some big swings with high-risk/high-reward pipeline candidates that
haven't really worked out as hoped, but the pipeline still appears deep
and broad enough to keep this supertanker-like pharma company moving
forward at a steady pace.
Follow this link for more:
GlaxoSmithKline PLC: The All-Weather Dividend Giant
No comments:
Post a Comment